Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
// Konrad Gabrusiewicz 1,* , Dan Liu 1,* , Nahir Cortes-Santiago 1,* , Mohammad B. Hossain 1 , Charles A. Conrad 1 , Kenneth D. Aldape 2 , Gregory N. Fuller 2 , Frank C. Marini 3 , Marta M. Alonso 4 , Miguel Angel Idoate 5 , Mark R. Gilbert 1 , Juan Fueyo 1 , and Candelaria Gomez-Manzano 1,6 1 Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3 Institute of Regenerative Medicine, Wake Forest University, Winston-Salem, North Carolina, USA 4 Department of Medical Oncology, University Hospital of Navarra, Pamplona, Spain 5 Department of Pathology, University Hospital of Navarra, Pamplona, Spain 6 Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA * contributed equally to the work Correspondence: Candelaria Gomez-Manzano, email: // Keywords : Brain tumors, antiangiogenesis, Tie2, tumor microenvironment, monocyte Received : January 6, 2014 Accepted : April 11, 2014 Published : April 11, 2014 Abstract The addition of anti-angiogenic therapy to the few treatments available to patients with malignant gliomas was based on the fact that these tumors are highly vascularized and on encouraging results from preclinical and clinical studies. However, tumors that initially respond to this therapy invariably recur with the acquisition of a highly aggressive and invasive phenotype. Although several myeloid populations have been associated to this pattern of recurrence, a specific targetable population has not been yet identified. Here, we present evidence for the accumulation of Tie2-expressing monocytes/macrophages (TEMs) at the tumor/normal brain interface of mice treated with anti-VEGF therapies in regions with heightened tumoral invasion. Furthermore, we describe the presence of TEMs in malignant glioma surgical specimens that recurred after bevacizumab treatment. Our studies showed that TEMs enhanced the invasive properties of glioma cells and secreted high levels of gelatinase enzymatic proteins. Accordingly, Tie2 + MMP9 + monocytic cells were consistently detected in the invasive tumor edge upon anti-VEGF therapies. Our results suggest the presence of a specific myeloid/monocytic subpopulation that plays a pivotal role in the mechanism of escape of malignant gliomas from anti-VEGF therapies and therefore constitutes a new cellular target for combination therapies in patients selected for anti-angiogenesis treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×
“The regulation of invasiveness and angiogenesis seems to be tightly interdependent: co-option of normal blood vessels by infiltrating glioma cells has been shown to be instrumental to the invasiveness of malignant glioma and to be a precursor to neovascularization [9, 34-36].”
BackgroundA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834 · cited 1×
“However, current evidence from experimental and clinical studies suggests that glioblastomas can recur after these therapies [10, 11] as highly aggressive tumors characterized by enhanced invasiveness and resistance to all currently available therapies [9, 12-16].”
BackgroundSelf-citationThe role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642 · cited 2×
“Several cytokines, including angiopoietin 2, and chemokines CCL3, CCL5, and CCL8, have been reported as chemoattractant molecules for TEMs [40].”
BackgroundExciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
De Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311
Macrophages in Tumor Microenvironments and the Progression of Tumors
Hao, N.-B., Lü, M.-H., Fan, Y.-H., Cao, Y.-L., Zhang, Z.-R., & Yang, S.-M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/948098 · Cited by 1,003 · cited 1×
“To understand the role of stroma on invasive glioma growth, we analyzed first for the presence of microglia/macrophages, which have been reported to be associated with adaptive resistance to anti-angiogenic therapy [27, 28].”
BackgroundTumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · cited 1×
“In murine preclinical models of lung cancer and lymphoma, refractoriness to anti-VEGF therapy was linked to tumor infiltration of CD11b+Gr1+ myeloid cells [17].”
BackgroundThe role of matrix metalloproteinases in glioma invasion
Nakada, M. (2003) · Frontiers in Bioscience · doi:10.2741/1016 · Cited by 201
Cited by
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Targeting VEGF/VEGFR to modulate antitumor immunity
Yang, J., Yan, J., & Liu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00978 · Cited by 646
“In addition to ovarian cancer, increased TAMs have been observed in the specimens of glioblastomas which progress during bevacizumab treatment and associated with a poor outcome in preclinical and clinical studies (98, 99).”
BackgroundThe interaction of anticancer therapies with tumor-associated macrophages
Mantovani, A., & Allavena, P. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150295 · Cited by 616
Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525360113 · Cited by 357
Metadata
- Authors
- Gabrusiewicz, K., Liu, D., Cortes-Santiago, N., Hossain, M. B., Conrad, C. A., Aldape, K. D., Fuller, G. N., Marini, F. C., Alonso, M. M., Idoate, M. A., Gilbert, M. R., Fueyo, J., & Gomez-Manzano, C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-04-11
- Volume
- 5
- Issue
- 8
- Pages
- 2208-2220
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1556310643
- Cited by
- 84
- References
- 8
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.